William Blair Brokers Decrease Earnings Estimates for SPRY

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Stock analysts at William Blair cut their Q1 2025 earnings per share estimates for shares of ARS Pharmaceuticals in a research report issued to clients and investors on Thursday, March 20th. William Blair analyst L. Hanbury-Brown now expects that the company will post earnings of ($0.35) per share for the quarter, down from their previous estimate of ($0.25). William Blair has a “Outperform” rating on the stock. The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.55) per share. William Blair also issued estimates for ARS Pharmaceuticals’ Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.39) EPS and FY2026 earnings at ($0.14) EPS.

Several other analysts have also recently commented on SPRY. Raymond James increased their price target on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a “strong-buy” rating in a research note on Tuesday, January 14th. Leerink Partners upped their price objective on ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Oppenheimer assumed coverage on ARS Pharmaceuticals in a research note on Monday, February 10th. They issued an “outperform” rating and a $40.00 target price for the company. Finally, Scotiabank started coverage on ARS Pharmaceuticals in a research report on Friday, March 7th. They set a “sector outperform” rating and a $30.00 target price for the company. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, ARS Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $31.00.

ARS Pharmaceuticals Trading Up 4.3 %

SPRY opened at $12.89 on Monday. ARS Pharmaceuticals has a 1-year low of $7.55 and a 1-year high of $18.51. The stock has a market capitalization of $1.25 billion, a PE ratio of -25.27 and a beta of 1.03. The firm has a 50-day moving average price of $12.10 and a two-hundred day moving average price of $13.06.

ARS Pharmaceuticals (NASDAQ:SPRY) last released its quarterly earnings results on Thursday, March 20th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.56. The business had revenue of $86.58 million during the quarter, compared to the consensus estimate of $15.46 million.

Hedge Funds Weigh In On ARS Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Alliancebernstein L.P. raised its position in shares of ARS Pharmaceuticals by 5,168.4% in the 4th quarter. Alliancebernstein L.P. now owns 3,880,734 shares of the company’s stock valued at $40,942,000 after acquiring an additional 3,807,074 shares during the period. Alyeska Investment Group L.P. raised its holdings in ARS Pharmaceuticals by 903.0% in the fourth quarter. Alyeska Investment Group L.P. now owns 1,253,724 shares of the company’s stock worth $13,227,000 after purchasing an additional 1,128,724 shares during the period. Raymond James Financial Inc. acquired a new stake in ARS Pharmaceuticals in the fourth quarter worth $6,576,000. Millennium Management LLC boosted its position in shares of ARS Pharmaceuticals by 93.0% during the fourth quarter. Millennium Management LLC now owns 939,278 shares of the company’s stock worth $9,909,000 after purchasing an additional 452,532 shares in the last quarter. Finally, Peregrine Capital Management LLC acquired a new position in shares of ARS Pharmaceuticals in the 4th quarter valued at $4,469,000. 68.16% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at ARS Pharmaceuticals

In related news, insider Eric Karas sold 10,000 shares of ARS Pharmaceuticals stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $14.00, for a total transaction of $140,000.00. Following the completion of the sale, the insider now directly owns 7,696 shares of the company’s stock, valued at $107,744. The trade was a 56.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Laura Shawver sold 50,000 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $12.31, for a total value of $615,500.00. Following the completion of the transaction, the director now directly owns 210,346 shares in the company, valued at $2,589,359.26. The trade was a 19.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 159,600 shares of company stock worth $1,866,516 over the last ninety days. Company insiders own 40.10% of the company’s stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.